trending Market Intelligence /marketintelligence/en/news-insights/trending/exwl46cphyzmbdyzhqc_yg2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

RavenQuest BioMed to buy 51% of Elephant Extracts


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

RavenQuest BioMed to buy 51% of Elephant Extracts

RavenQuest BioMed Inc. intends to acquire 51% of Elephant Extracts' outstanding share capital.

The Vancouver, British Columbia-based cannabis producer entered into a letter of intent with Elephant Extracts, whose official business name is 1090252 B.C. Ltd., to acquire a controlling interest in the company.

Elephant Extracts may redeem the interest after it receives a license to produce under Canada's Access to Cannabis for Medical Purposes Regulations. RavenQuest will be granted an ongoing royalty of 15% of the gross revenue from production at a 10,000 square foot facility developed by Elephant Extracts.

Completion of the deal is subject to completion of due diligence, a definitive agreement and regulatory approvals.